OncoMatch/Clinical Trials/NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Is NCT06841354 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for triple negative breast neoplasms.

Phase 3RecruitingMerck Sharp & Dohme LLCNCT06841354Data as of May 2026

Treatment: Sacituzumab tirumotecan · Pembrolizumab · Rescue Medication · Paclitaxel · Nab-paclitaxel · Gemcitabine · Carboplatin — Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Triple-Negative Breast Cancer

Breast Carcinoma

Biomarker criteria

Excluded: PD-L1 (CD274) overexpression (CPS ≥10)

TNBC with evaluable tumor programmed death ligand 1 (PD-L1) expression at combined positive score (CPS) ≥10

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: systemic therapy

Exception: prior therapy for early-stage breast cancer completed at least 6 months before first disease recurrence

Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

USA Mitchell Cancer Institute ( Site 0090) · Mobile, Alabama
Ironwood Cancer & Research Centers ( Site 0036) · Chandler, Arizona
City of Hope ( Site 0097) · Duarte, California
City of Hope Lennar Foundation Cancer Center ( Site 0099) · Irvine, California
UCLA Department of Medicine - Hematology & Oncology ( Site 0047) · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify